fda announcement tirzepatide 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these FDA moves to limit compounding

Withdraw the prescribed volume (e.g., 0.25, 0.5, 0.75 or 1 mL) into a sterile syringe and inject subcutaneously in the abdomen, thigh, or upper arm after cleaning the site with alcohol

Regular check-ups with healthcare providers can help manage these risks and ensure overall health

Regulatory implications: These differences formed the basis of Novo Nordisks formal petition nominating semaglutide for the FDAs Demonstrable Difficulties for Compounding (DDC) lists arguing that the complexity of replicating recombinant semaglutide through synthetic compounding makes it inherently unsuitable for routine compounding

Several protein sources increase GLP-1 release (Miguens-Gomez et al 2021)

The prevalence of NAFLD has increased rapidly over the last two decades, in parallel with the dramatic rise in obesity and diabetes

Our plans help you manage weight and balance hormones for better health